Transneural Therapeutics Inc. has described 5-HT2A receptor modulators reported to be useful for the treatment of depression, anxiety, substance abuse and dependence, and headache.

Laboratory tests of a novel serotonin-binding compound have revealed an unexpected disconnect between receptor activation and ...

Entheogenix Biosciences Inc. has described 5-HT2A receptor agonists reported to be useful for the treatment of post-traumatic stress, depression and anxiety disorders.

Psychedelics activate the 5-HT2A receptor, upregulate brain-derived neurotrophic factor, and enhance synaptic plasticity, leading to therapeutic potential for stress and psychiatric disorders. Credit ...

Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest research, Treatment with shRNA to ...

This article and associated images are based on a poster originally authored by Elisabetta Perdona, Palmina Cavallini, Alessia Auber, Mattia Musto, Martina Antolini, Stefania Faedo, Giovanni Benedetti ...

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Serotonergic psychedelics, such as psilocybin and LSD, are also commonly referred to as hallucinogens because at higher "trip-inducing" doses (as opposed to microdoses), these drugs typically trigger ...

The BMJ is an international peer reviewed medical journal and a fully "online first" publication. Our publishing model–"continuous publication"– means that all articles appear on bmj.com before being ...